JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.65B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.08B |
| 3 |
Microsoft
MSFT
|
+$2.05B |
| 4 |
Vanguard Total International Bond ETF
BNDX
|
+$1.64B |
| 5 |
Micron Technology
MU
|
+$1.39B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMJ
JP Morgan Alerian MLP Index ETN 5/24/24
AMJ
|
+$2.4B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.11B |
| 3 |
Progressive
PGR
|
+$1.64B |
| 4 |
Salesforce
CRM
|
+$1.54B |
| 5 |
Adobe
ADBE
|
+$1.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.03% |
| 2 | Healthcare | 9.24% |
| 3 | Consumer Discretionary | 8.79% |
| 4 | Financials | 8.61% |
| 5 | Industrials | 6.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
5276
Microvision
MVIS
$89.7M
| $98.7K | ﹤0.01% |
6,208
-14,757
| -70% | -$291K |
|
|
CTEV
5277
Claritev Corp
CTEV
$716M
| $98.6K | ﹤0.01% |
6,346
-50,648
| -89% | -$1.21M |
|
|
INZY
5278
DELISTED
Inozyme Pharma
INZY
| $98.5K | ﹤0.01% |
22,077
-39,500
| -64% | -$192K |
|
5279
Omeros
OMER
$1.26B
| $98.4K | ﹤0.01% |
24,233
-2,395
| -9% | -$8.56K |
|
5280
Virginia National Bankshares
VABK
$254M
| $98.2K | ﹤0.01% |
2,994
-3,597
| -55% | -$105K |
|
5281
FT Vest US Equity Moderate Buffer ETF September
GSEP
$345M
| $97.8K | ﹤0.01% |
+2,894
| New | +$96.2K |
|
|
SPWRW
5282
SunPower Inc Warrants
SPWRW
$745K
| – | – |
0
| – | – |
|
5283
Innovator US Equity Ultra Buffer ETF October
UOCT
$181M
| $97.6K | ﹤0.01% |
2,848
| – | – |
|
5284
Northern Technologies International Corp
NTIC
$76.7M
| $97.6K | ﹤0.01% |
5,892
+5,098
| +642% | +$84.7K |
|
5285
iShares Global Consumer Staples ETF
KXI
$1.07B
| $97.4K | ﹤0.01% |
1,620
-4,488
| -73% | -$273K |
|
5286
Invesco Pharmaceuticals ETF
PJP
$497M
| $97.3K | ﹤0.01% |
1,184
-2,981
| -72% | -$237K |
|
5287
Codexis
CDXS
$175M
| $96.6K | ﹤0.01% |
31,172
-12,242
| -28% | -$39.3K |
|
|
AEVA
5288
Aeva Technologies
AEVA
$1.56B
| $96.5K | ﹤0.01% |
38,285
+792
| +2% | +$2.58K |
|
|
HUDAR
5289
DELISTED
Hudson Acquisition I Corp. Right
HUDAR
| $96K | ﹤0.01% |
400,000
-11,861
| -3% | -$2.94K |
|
5290
Invesco Zacks Mid-Cap ETF
CZA
$193M
| $96K | ﹤0.01% |
983
-40
| -4% | -$3.94K |
|
5291
CALL
VF Corp
VFC
$5.79B
| $95.8K | ﹤0.01% |
7,100
| – | – |
|
5292
TScan Therapeutics
TCRX
$52.3M
| $95.7K | ﹤0.01% |
16,364
-50,649
| -76% | -$399K |
|
5293
Fidelity MSCI Utilities Index ETF
FUTY
$2.31B
| $95.3K | ﹤0.01% |
2,168
-5,540
| -72% | -$245K |
|
5294
Mama's Creations
MAMA
$790M
| $94.5K | ﹤0.01% |
14,025
-107,000
| -88% | -$652K |
|
5295
CALL
Syndax Pharmaceuticals
SNDX
$1.7B
| $94.4K | ﹤0.01% |
4,600
| – | – |
|
5296
ADC Therapeutics
ADCT
$134M
| $94.3K | ﹤0.01% |
+29,837
| New | +$119K |
|
5297
LivePerson
LPSN
$35.9M
| $93.8K | ﹤0.01% |
10,773
+8,721
| +425% | +$83.8K |
|
|
LENZ
5298
LENZ Therapeutics
LENZ
$145M
| $93.7K | ﹤0.01% |
5,420
+3,738
| +222% | +$65.3K |
|
5299
Trevi Therapeutics
TRVI
$2.59B
| $93.4K | ﹤0.01% |
31,350
+5,887
| +23% | +$16.4K |
|
5300
Nuvectis Pharma
NVCT
$627M
| $93.4K | ﹤0.01% |
14,753
+9,588
| +186% | +$65.2K |
|
Similar funds
JP Morgan Chase's Q2 2024 Portfolio in Review
As of Q2 2024, JP Morgan Chase held 7,917 positions worth $1.22T, up 3% from $1.18T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q2 2024 filing shows 549 new, 2,512 increased, 3,286 reduced and 579 closed positions. Its largest new stake was BlackRock Flexible Income ETF: 6,829,171 shares worth $357M. The largest sale was JP Morgan Alerian MLP Index ETN 5/24/24, an estimated $2.4B.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- JP Morgan Chase's largest Q2 2024 buy was BlackRock Flexible Income ETF: 6,829,171 shares worth $357M.
- JP Morgan Chase added most to Apple in Q2 2024, an estimated $4.65B increase.
- JP Morgan Chase's biggest Q2 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $2.11B.
- JP Morgan Chase fully exited JP Morgan Alerian MLP Index ETN 5/24/24 in Q2 2024, selling an estimated $2.4B.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.22T portfolio in Q2 2024.
- JP Morgan Chase opened 549 new positions and closed 579 in Q2 2024.
- JP Morgan Chase's portfolio value rose 3% quarter-over-quarter to $1.22T.
Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.